Oct 18, · Bitcoin’s utility is as money. It has a market because it solves a problem inherent in modern money. Not only is bitcoin not a pyramid scheme; it is fundamentally distinct from the class of innovation that could be offered by any individual company. Bitcoin is not Dell and it is not Apple. Jan 04, · One of the leading financial media outlets just called Bitcoin a grand pyramid scheme. It doesn’t come as a surprise as it’s common among mainstream media outlets to sensationalize news to gain more readership. Bitcoin is an ideal topic to do just that. Jul 14, · A pyramid scheme is a Bitcoin scandal has a slightly different structure than that of the treacherous Ponzi scheme. In a pyramid scheme, recruiters hire some people for some tasks and ask them to recruit more in a long chain, adding a number of layers to sustain the bottom for operation.5/5(1).
Pyramid scheme bitcoinBitcoin is a pyramid scheme, economist says
After failing as a medium of exchange, it is now considered to be a store of value. With that being said, a Deutsche Bank analyst predicted that the s could be the decade of crypto. Alex Dovbnya aka AlexMorris is a cryptocurrency expert, trader and journalist with extensive experience of covering everything related to the burgeoning industry — from price analysis to Blockchain disruption. Alex authored more than 1, stories for U. Today, CryptoComes and other fintech media outlets.
Bitcoin Is a Pyramid Scheme. Alex Dovbnya Tendayi Kapfidze is certain that Bitcoin is simply a pyramid scheme that struggles to find a use case after making its early adopters rich. About the author. Alex Dovbnya. Yuri Molchan.
They do. Only Buy ratings, 3, in fact, have been issued in the last three months. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment. The Alibaba Trades: On Tuesday morning, Benzinga Pro subscribers received dozens of option alerts related to unusually large Alibaba option trades. Why It's Important: Even traders who stick exclusively to stocks often monitor option market activity closely for unusually large trades.
Given the relative complexity of the options market, large options traders are typically considered to be more sophisticated than the average stock trader. Many of these large options traders are wealthy individuals or institutions who may have unique information or theses related to the underlying stock.
Unfortunately, stock traders often use the options market to hedge against their larger stock positions, and there's no surefire way to determine if an options trade is a standalone position or a hedge. In this case, given the relatively large sizes of Tuesday's biggest Alibaba option trades, they could certainly be institutional hedging.
China has cracked down on Alibaba and its affiliate Ant Financial after Ma made critical comments about Chinese government regulators back in October. Ma hasn't made a public appearance in months, leading some to speculate that the Chinese Communist Party had Ma imprisoned or worse following his comments.
While Alibaba is far from out of the woods when it comes to the regulatory crackdown, CNBC reported Ma has simply been lying low and avoiding the public eye since his controversial comments. Benzinga does not provide investment advice. All rights reserved. Two analysts are raising their price targets on Apple stock, with both taking note of strong demand for the new iPhone 12 phone lineup.
PFE is dropping the big blue pill for something a bit more… science-y. The rebranding comes as Pfizer ticker: PFE completes a slimming-down that has seen it shed a range of businesses, to focus almost entirely on inventing and buying new drugs.
A new year, a new addition to the stock portfolio — what can make more sense than that? The right time to buy, of course, is when stocks are priced at the bottom. But the markets are up. With a market environment like that, finding stocks that are caught in the doldrums is harder than it looks. That's where the Wall Street pros can lend a hand. Not to mention each has earned a Moderate or Strong Buy consensus rating.
Esperion ESPR We will start with Esperion, a company that specializes in therapies for the treatment of elevated low-density lipoprotein cholesterol levels — a major factor contributing to heart disease. Bempedoic acid remains in clinical trials of its efficacy in risk reduction for cardiovascular disease.
The trial, called CLEAR Outcomes, is a large-scale, long-term study, tracking more than 14, patients with top-line data expected in the second half of The study covers 1, locations in 32 countries around the world.
Esperion shares peaked last February, after the FDA approvals, but since then, the stock has declined. The offering gives the company a boost in available capital for further work on its development pipeline and its marketing efforts for bempedoic acid. We believe this financing should help put to rest concerns regarding Esperion's balance sheet.
This growth trajectory suggests potential for a rapid acceleration when conditions improve," Messer wrote. Intercept has a research pipeline based on FXR, a regulator of bile acid pathways in the hepatic system. The effect on the stock is still felt, and ICPT remains at its week low point.
In reaction, in December of , Intercept announced major changes in top-level management, as CEO and President Mark Pruzanski announced he's stepping down effective January 1 of this year. Pruzanski's dedication to transform the liver space is still strong, and that he will continue to guide ICPT's progress as an advisor and Board member.
By November, however, even though remdesivir had been approved, the World Health Organization WHO was recommending against its use, and the COVID vaccines now on the market have made remdesivir irrelevant to the pandemic. The company has been working, in conjunction with Galapagos GLPG , on development of filgotinib as a treatment for rheumatoid arthritis.
Looking at the consensus breakdown, opinions from other analysts are more spread out. The analyst raised the volume estimate to 5. The analyst said the market has chosen to discount the value of Tesla compared to peers despite a range of high outcomes. It's hard to find a more innovative company, especially in the electric vehicle and autonomous vehicle markets said Jonas calling Tesla the best positioned.